What is it about?
Ciprofloxacin resistance for Shigella isolates is becoming more prevalent. We have shown that the ciprofloxacin/fosfomycin combination induced synergy, and increased bacterial killing in vitro and in a simple invertebrate model of infection against S. flexneri isolates of ciprofloxacin resistance.
Featured Image
Why is it important?
To the best of our knowledge, our study is the first to confirm the ciprofloxacin/fosfomycin combination enhanced in vitro and in vivo activity against S. flexneri isolates of ciprofloxacin resistance.
Perspectives
I hope this article can help to understand the synergistic effect of ciprofloxacin combined with fosfomycin and to developing more effective therapy against S. flexneri isolates of ciprofloxacin resistance.
Jiabin Li
Anhui Medical University
Read the Original
This page is a summary of: In vitro and in vivo activity of ciprofloxacin/fosfomycin combination therapy against ciprofloxacin-resistant Shigella flexneri isolates, Infection and Drug Resistance, June 2019, Dove Medical Press,
DOI: 10.2147/idr.s208071.
You can read the full text:
Resources
Contributors
The following have contributed to this page
